Advertisement
Advertisement
U.S. Markets open in 3 hrs 40 mins
Advertisement
Advertisement
Advertisement
Advertisement

Aptose Biosciences Inc. (APTO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0400+0.0400 (+4.00%)
At close: 04:00PM EDT
1.0600 +0.02 (+1.92%)
Pre-Market: 04:00AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0000
Open1.0500
Bid0.0000 x 1000
Ask0.0000 x 900
Day's Range1.0000 - 1.0800
52 Week Range0.9000 - 5.7800
Volume295,584
Avg. Volume450,811
Market Cap92.986M
Beta (5Y Monthly)1.12
PE Ratio (TTM)N/A
EPS (TTM)-0.6270
Earnings DateMar 21, 2022 - Mar 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.86
  • GlobeNewswire

    Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd

    Clinical Updates for HM43239 and Luxeptinib Poster Presentation for HM43239 is Scheduled for June 10th at EHA2022 Hybrid Congress SAN DIEGO and TORONTO, May 12, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the company management team, along with guest key opinion leaders (KOLs), will p

  • GlobeNewswire

    Aptose Reports Results for the First Quarter 2022

    Expands HM43239 dose cohort at 160 mg Headway with luxeptinib “G3” formulation in patients Conference call and webcast at 5:00 pm ET today SAN DIEGO and TORONTO, May 09, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the three months ended March 31, 2022 and provided a c

  • GlobeNewswire

    Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation

    SAN DIEGO and TORONTO, May 04, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukem

Advertisement
Advertisement